Earnings ·
PepGen Inc. reported second quarter 2026 financial results and clinical updates for its investigational therapy…
PEPGPepGen Inc.
PepGen Inc. reported second quarter 2026 financial results and clinical updates for its investigational therapy PGN-EDODM1, which targets myotonic dystrophy type 1 (DM1). The company held $117.2 million in cash as of June 30, 2026, sufficient to fund operations into the fourth quarter of 2027. For the quarter ended June 30, 2026, PepGen reported a net loss of $17.8 million, or $(0.26) per share, compared to a net loss of $23.1 million in the prior year period. Research and development expenses decreased to $12.5 million from $18.4 million, while general and administrative expenses rose to $6.4 million from $5.5 million. Clinically, an independent Data and Safety Monitoring Board recommended advancing the Phase 2 FREEDOM2-DM1 study into the highest dose cohort of 12.5 mg/kg and escalating doses in the open-label extension study from 5 mg/kg to 10 mg/kg based on favorable safety data. PepGen Inc. is a clinical-stage biotechnology company developing oligonucleotide therapies for severe neuromuscular and neurological diseases.